Therefore, these SD-DC expressing PRKAR1A boosted autologous effector-T-cell antitumor activity, significantly promoting their cytotoxic activity against CCA, thus representing a promising strategy to develop novel therapies to tackle CCA [98]. This evidence concerns the gene PRKAR1A and cholangiocarcinoma.